 These studies included a Phase I open-label study, a Phase III randomized, double-blind, placebo-controlled study, and a Phase III open-label extension study.A Phase 2 Young Pediatric study was also conducted.Clinical trials and post-market safety data indicate that the most common adverse side effect of Aldurazyme is allergic reaction.